*素高捷疗针剂
出处：按学科分类—医药、卫生 军事医学科学出版社《临床常用进口药物手册》第455页（5268字）
【中文释文】：
每安瓿2ml，5ml，10ml
〔成分〕
1ml注射剂含40mg素高捷疗。
〔性质及疗效〕
缺血受损的组织在修复过程中极需大量的能量，素高捷疗可激发及加快修复过程，特别适用于供氧不足的状况下，改善氧的利用率，并促进养分穿透入细胞。
细胞内三磷酸腺苷的形成数量大增，正好是能量供应特别的事实。最新研究显示，素高捷疗的药代动力学效应，着重于维持生物膜功能的性质上。
素高捷疗以Warburg法标定，能使氧的利用率增加超过200%。素高捷疗在氧供应甚差的组织内也能提高氧的利用率。
体内使用正常人常用量的20倍，素高捷疗在各项急慢性的研究中从未发现中毒反应。广泛临床所得的结论证实即使大剂量使用素高捷疗也绝无危险。
〔适应证〕
脑循环障碍，脑代谢障碍：神经官能症状，脑血管硬化，中风，脑创伤；末梢周围循环障碍，严重灼伤，心肌梗塞的辅助治疗。
〔一般剂量〕
每日静脉或动脉注射5～10ml。若不能静脉注射，同剂量的素高捷疗也可分成数次作肌肉注射或分成数份在身体不同部位作肌肉注射。
每一种指征有特别的剂量指引须加留意。
治疗期一般4～6疗程，视病情而定。
〔使用限制〕
素高捷疗是高渗液(约1100mmol／L)，为避免引起静脉炎，静脉注射宜慢。超过10ml的剂量宜用5%葡萄糖液等稀释，作滴注给药。
素高捷疗含微量对羟苯甲酸(E216和E218)及相应的游离酸(E210)，须留意病人对这些物质是否过敏。
〔不良反应〕
从未发现。
〔相互作用〕
针剂加入电解质、葡萄糖或果糖溶液中无发现不配性。与其他溶液混和，即使混和液清澈，也可能有隐蔽性配伍禁忌。
〔过量〕
从无过量引发的症状或不适报道。
〔生产厂家〕
瑞士巴塞尔素高大药厂
【外文释文】：
Ampoules of 2 ml，5 ml，10 ml
Composition
1 ml injectable contains
40 mg Solcoseryl
Properties／Effects
Solcoseryl improves oxygen utilization，especially under conditions of hypoxia，and promotes the penetration of nutrients into the cell．This stimulates and speeds up the repair processes，which have a high energy demand，in the areas of tissue which have suffered ischaemic damage．
The fact that energy is supplied is evident from，inter alia，the marked increase in the formation of intracellular adenosine triphosphate(ATP)．Recent investigations have shown that the pharmacodynamic effects of Solcoseryl are essentially based on its property of maintaining the functioning of biological membranes．
Solcoseryl is standardized by the Warburg method and increases oxygen utilization by more than 200%，Solcoseryl improves oxygen utilization even in tissues with a poor O2 supply．
No toxic effects have been observed in either acute or chronic studies on various species with parenteral administration of doses of Solcoseryl which correspond to 20 times the normal daily dose for humans．Thus，the conclusion for the clinics is that administration ofSolcoseryl even at high dosage，entails hardly any safety risks，and this has been confirmed by extensive clinical experience．
Indications
Disorders of cerebral circulation and metabolism：
Psycho-organic syndrome，cerebral sclerosis，apoplectic insults，skull and brain traumata．
Disturbances of peripheral circulation，severe burn and supportive myocardial infarction treatment．
Solcoseryl in cerebrovascular disorders
In cerebral insults the main effect of Solcoseryl is its capacity to speed up the return to normal of reversibly damaged cells in the“ischaemic penumbra”or“perinecrotic zone”．The chemical nature of the isolated glycolipids in Solcoseryl suggests that a membrane stabilizing effect may be involved and that this enables reversibly damaged cells to quickly recover their capacity to respond to the physiological mechanisms controlling the biological system．This working hypothesis would certainly account for the relatively broad spectrum of indications of the preparation，as the therapeutic activity would be present whenever biological systems were reversibly damaged at the cellular level．
Usual dosage
Daily，5-10 ml，intravenous or intraarterial．When the intravenous injection is not possible，the same dosage of Solcoseryl can be divided into several intramuscular injections spread over the day or distributed over various injection places．
For each one of the indications the special dosage instructions should be observed．The duration of treatment is generally of 4 or 6 weeks and depends upon the clinical course of the disease．
Restrictions on use
Solcoseryl is a hypertonic solution(ca 1100 moSm／L)．To avoid occurrence of phlebitis，iv injections by peripheral veins should be administered slowly．Dosages over 10 ml should preferably be diluted(e．g．5%glucose solution)and be given as drop infusions．
Solcoseryl contains manufacturing traces of p-hydroxybenzoates(E 216 and E 218)and the corresponding free acid(E 210)，what must be taken into account in patients known to be allergic to these compounds．
Adverse reactions
None nitherto known．
Interactions
Addtion of Solcoseryl ampoule solution to infusion fluids such as electrolytes，glucose or fructose has resulted in no known incompatibilities．Mixing Solcoseryl with other infusion fluids may result in masked incompatibility in spite of the fact that the infusion mixture remains clear．
Overdosage
No symptoms or signs resulting from overdosage have been reported until now．
Manufacturer
Solco Basle，Ltd．，Birsfelden-Basle，Switzerland